Comorbid diseases of <scp>I</scp>g<scp>G</scp>4‐related sialadenitis in the head and neck region

Xiang, Hong; Sun, Zhipeng; Li, Wei; Chen, Yan; Gao, Yan; Su, Jia-Zeng; Wang, Zhen; Cai, Zhi‐Gang; Li, Tongtong; Zhang, Lei; Liu, Xiaojing; Li, Yanying; He, Jing; Li, Zhanguo; Yu, Guang‐Yan

doi:10.1002/lary.25387

Cited by 18 publications

(13 citation statements)

References 41 publications

(86 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Несмотря на их большую распространенность среди пациентов с IgG4-СЗ, отдельных работ, посвященных исследованию IgG4-связанных поражений носа/параназальных синусов, очень мало. Клинические и рентгенологические признаки хронического риносинусита (ХРС) при IgG4-СЗ неотличимы от проявлений «обычного» ХРС, а диагностическая значимость наличия IgG4+ клеток в слизистой носа остается спорной [36]. Все это вызывает значительные сложности в правильной трактовке имеющихся симптомов, особенно в случаях с дебютом IgG4-СЗ с ХРС в отсутствие других характерных очагов поражений.…”

Section: ýòèîëîãèÿ è ïàòîãåíåçunclassified

“…Все это вызывает значительные сложности в правильной трактовке имеющихся симптомов, особенно в случаях с дебютом IgG4-СЗ с ХРС в отсутствие других характерных очагов поражений. Также существуют разногласия среди исследователей, является ли ХРС самостоятельным проявлением IgG4-СЗ [36].…”

Section: ýòèîëîãèÿ è ïàòîãåíåçunclassified

See 1 more Smart Citation

IgG4-related disease: what do we know after 20 years

Sokol

2020

Terapevticheskii arkhiv

View full text Add to dashboard Cite

IgG4-related disease is immunomediated fibroinflammatory condition, characterized by tumefective lesions in different organs with distinctive pathomorphological features and IgG4 hypersecretion in serum and tissues in the majority of patients. IgG4-RD has been established as a separate clinical in the early 2000s. In the review we focus on the evolution of views on ethiopathogenesis of the disease, therapeutic and diagnostic options and classification of the disease.

show abstract

Section: ýòèîëîãèÿ è ïàòîãåíåçunclassified

IgG4-related disease: what do we know after 20 years

Sokol

2020

Terapevticheskii arkhiv

View full text Add to dashboard Cite

show abstract

“…On the other hand, patients with IgG4‐RS suffer more frequently (15–30%) from AIP, sclerosing cholangitis, and asthma, compared to the primary SS counterparts (Moriyama et al , ; Mavragani et al , ; Li et al , ). Nose, paranasal sinuses, and ears are also very often (>50%) involved along with the salivary and lacrimal glands in IgG4‐RS (Hong et al , ). Cervical lymphadenopathy is found in about 70 % of the patients and should therefore raise the suspicion of IgG4‐RS in patients with enlarged salivary glands (Li et al , ).…”

Section: Differential Diagnosis: Igg4‐related Sialadenitis and Sjögrementioning

confidence: 99%

IgG4‐related sialadenitis and Sjögren's syndrome

2016

View full text Add to dashboard Cite

IgG4-related disease (IgG4-RD) has emerged as a new entity in the last decade. It comprises numerous conditions previously thought to be unrelated. Macroscopically, these diseases cause diffuse organ swelling and formation of pseudotumorous masses. Histopathologically, they are characterized by a lymphoplasmacytic infiltrate with increased IgG4+ plasma cells and storiform fibrosis. Despite rapid progress within the last years, our knowledge on these conditions is still fragmented. To date, more than forty organs have been reported to be included in IgG4-RD, and salivary gland involvement is amongst the most common organs affected [IgG4-related sialadenitis (IgG4-RS)]. Interestingly, IgG4-RS shares commonalities with Sjögren's syndrome (SS), like glandular enlargement, sicca symptoms, arthralgias, hypergammaglobulinemia, hypocomplementemia, and circulating antinuclear antibodies. Nonetheless, they differ in that the incidence of anti-Ro and anti-La reactivity is not frequently found in patients with IgG4-RS, their salivary glands are infiltrated by a large number of IgG4+ plasma cells and IgG4-RS symptoms respond promptly to steroids. The aim of this review was to describe the clinical, serological, histopathological and pathophysiological aspects of IgG4-RS in the context of IgG4-RD and highlight the differences between IgG4-RS and SS.

show abstract

“…IgG4‐related dacryoadenitis and sialadenitis (IgG4‐DS) is a kind of IgG4‐related disease (IgG‐RD), a rare chronic immune‐mediated disease that occurs in the oral and maxillofacial region and is closely related to IgG4‐positive plasma cells (Brito‐Zeron et al, 2014; Hong, Sun, et al, 2015; Hong, Li, Li, Su, Wang, & Yu, 2015]. It mainly occurs in middle and old age and is characterized by diffuse swelling of the affected tissue, increased serum IgG4 (sIgG4) level, IgG4 + plasma cell infiltration, and tissue fibrosis.…”

Section: Introductionmentioning

confidence: 99%

Prediction of 3‐month treatment outcome of IgG4‐DS based on BP artificial neural network

et al. 2020

View full text Add to dashboard Cite

Objective The study aimed to establish an effective back‐Propagation artificial neural network (BP‐ANN) model for automatic prediction of 3‐month treatment outcome of IgG4‐DS. Methods A total of 26 IgG4‐DS patients at Shanghai Ninth People's Hospital from January 2018 to December 2019 were involved in the study. They were all followed for >3 months. The primary outcome was reduction of serum IgG4 (sIgG4) after 3‐month treatment. The association between risk factors and reduction of sIgG4 was analyzed by Spearman's rank correlation test. According to the R values, we built a BP‐ANN model by MATLAB R2019b. Results The average reduction of sIgG4 was 5.55 ± 5.03. After Spearman's rank correlation test, ESR, sIgG4, and sIgG were independently associated with reduction of sIgG4 (p < .05) and were selected as input variables. Take into account these parameters, BP‐ANN model was developed and the coefficient of determination (R2) model was 0.95512. Conclusion The BP‐ANN model based on ESR, sIgG4, and sIgG could predict the 3‐month reduction of sIgG4 for IgG4‐DS patients. It showed potential clinical application value.

show abstract

Comorbid diseases of IgG4‐related sialadenitis in the head and neck region

Abstract: 4.

Cited by 18 publications

References 41 publications

IgG4-related disease: what do we know after 20 years

IgG4-related disease: what do we know after 20 years

IgG4‐related sialadenitis and Sjögren's syndrome

Prediction of 3‐month treatment outcome of IgG4‐DS based on BP artificial neural network

Contact Info

Product

Resources

About